• 1
    Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629634.
  • 2
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257263.
  • 3
    Rostaing L, Izopet J, Baron E et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 (Suppl 6): 9396.
  • 4
    Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 21042106.
  • 5
    Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427437.
  • 6
    Meyers C, Seeff L, Stehman-Breen C, Hoofnagle J. Hepatitis C and renal disease: An update. Am J Kidney Dis 2003; 42: 631657.
  • 7
    Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after (-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 20922098.
  • 8
    Gonzalez-Roncero F, Gentil M, Valdivia M et al. Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 2003; 35: 17451747.
  • 9
    Cruzado J, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo J. Pretransplant Interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357360.
  • 10
    Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 27042709.
  • 11
    Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 16101615.
    Direct Link:
  • 12
    Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 10711081.
  • 13
    Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in Hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 7478.
  • 14
    Hanafusa T, Ichikawa Y, Yazawa K et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc. 1998; 30: 122124.
  • 15
    Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 14261431.
  • 16
    Rivera M, Gentil MA, Sayago M et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005; 37: 14241425.
  • 17
    Smak Gregoor PJ, Zietse R, Van Saase JL et al. Immunosuppression should be stopped in patients with renal allograft failure. Clin Transplant 2001; 15: 397401.
  • 18
    Kaplan B, Meier-Kriesche HU. Death after graft loss: An important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970974.
  • 19
    Hanrotel C, Toupance O, Lavaud S et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120126.
  • 20
    Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905915.
  • 21
    Gentil MA, Lopez M, Gonzalez-Roncero F et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: Influence of new immunosuppression protocols. Transplant Proc 2003; 35: 17481750.
  • 22
    Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2004; 65: 23352342.